Obicetrapib 10 mg

DRUG2 trials

Sponsors

NewAmsterdam Pharma

Conditions

LipidemiaMetabolic Syndrome (MetS)Preclinical Alzheimer's DiseaseType 2 Diabetes (T2DM)

Phase 2

Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease

Not yet recruitingNCT07794670

NewAmsterdam PharmaPreclinical Alzheimer's Disease

Start: 2026-09-01End: 2029-05-01Target: 400Updated: 2026-08-31

Phase 3

A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome

Active, not recruitingNCT07219602

NewAmsterdam PharmaLipidemia, Metabolic Syndrome (MetS), Type 2 Diabetes (T2DM)

Start: 2025-12-11End: 2028-06-01Target: 300Updated: 2026-09-09